The N-terminal aminoacid of phenethylamide tripeptide inhibitors of the hepatitis C virus NS3 protease can be replaced with an α-hydroxy acid to obtain more 'drug like'inhibitors with low micromolar activity. The preferred S-configuration of the capping residue can be explained by molecular modeling studies.